GO:0034653 retinoic acid catabolic process: Metabolism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034653 (retinoic acid catabolic process) describes the biochemical reactions that break down retinoic acid, the active vitamin A derivative that controls gene expression, cell differentiation and development.
• Catabolism of retinoic acid is essential to terminate retinoic acid signaling; it is mediated by cytochrome P450 enzymes (CYP26A1, CYP26B1, CYP26C1) and other oxidative enzymes that convert retinoic acid into more polar, inactive metabolites.
• Retinoic acid levels are tightly controlled by the balance between biosynthesis (retinaldehyde dehydrogenases) and catabolism (CYP26 enzymes), and this balance determines cell fate decisions in embryogenesis and hematopoiesis.
• Dysregulated retinoic acid catabolism contributes to cancer (e.g., acute myeloid leukemia, solid tumors), developmental disorders and neurodegeneration, making it a therapeutic target.
• Key experimental approaches to study GO:0034653 include CRISPR knockout/knock-in of CYP26 genes, LC-MS/MS quantification of retinoids, reporter assays for retinoic acid signaling, and transcriptomic/proteomic profiling.
• EDITGENE provides CRISPR cell model services (knockout, point mutation, knock-in, overexpression) and library screening to dissect retinoic acid catabolic pathways in disease-relevant contexts.
Description
Retinoic acid (RA) is a potent signaling molecule derived from vitamin A that regulates gene transcription, cell proliferation, differentiation and apoptosis. The biological activity of RA is terminated by its catabolic breakdown, a process formally described by the Gene Ontology term GO:0034653 (retinoic acid catabolic process). This process ensures that RA signals are transient and spatially restricted, which is critical for normal embryonic development and tissue homeostasis. At the molecular level, retinoic acid catabolism is primarily carried out by cytochrome P450 family 26 enzymes (CYP26A1, CYP26B1, CYP26C1), which oxidize RA into hydroxylated and eventually more polar metabolites that are excreted. The expression of these enzymes is itself regulated by RA, forming a negative feedback loop that prevents excessive RA signaling. Disruption of this balance leads to developmental defects, cancer and other diseases. For researchers, GO:0034653 provides a framework to study how cells control RA availability and how perturbations in catabolic enzymes affect differentiation, stem cell maintenance and tumorigenesis. Understanding this process is essential for developing therapies that modulate RA signaling, such as in acute promyelocytic leukemia (APL) and other malignancies.
retinoic acid catabolic process At A Glance
| GO ID | GO:0034653 |
|---|---|
| GO term | retinoic acid catabolic process |
| Ontology | biological_process |
| Synonym | retinoic acid breakdown; retinoic acid catabolism; retinoic acid degradation; vitamin A1 acid catabolic process |
| Major function | Breakdown of retinoic acid to terminate its signaling and maintain retinoid homeostasis |
| Key enzymes | CYP26A1, CYP26B1, CYP26C1, and other cytochrome P450 oxidases |
| Substrates | all-trans-retinoic acid, 9-cis-retinoic acid, 13-cis-retinoic acid |
| Pathways | Retinoid metabolism; cytochrome P450-mediated oxidation |
| Related processes | Retinoic acid biosynthetic process (GO:0042572), retinoic acid signaling |
What Is GO:0034653?
GO:0034653 (retinoic acid catabolic process) is defined as the chemical reactions and pathways resulting in the breakdown of retinoic acid, one of the three components that makes up vitamin A. In practice, this includes enzymatic oxidation steps that convert retinoic acid into less active or inactive metabolites, thereby terminating its signaling functions.
Why Is retinoic acid catabolic process Important in Cell Biology?
The catabolism of retinoic acid is a critical control point in development, adult tissue homeostasis and disease. By degrading RA, cells can rapidly switch off RA-dependent transcriptional programs, which is essential for proper patterning of the embryo, differentiation of hematopoietic cells and maintenance of epithelial tissues. Dysregulation of RA catabolism is linked to cancer, including acute myeloid leukemia and solid tumors, where altered CYP26 expression can lead to RA resistance or oncogenic signaling. Therefore, understanding GO:0034653 offers insights into basic biology and potential therapeutic strategies.
• Controls the duration and intensity of retinoic acid signaling, which is vital for embryonic development and organogenesis.
• Regulates hematopoietic stem cell differentiation and myeloid lineage commitment; its disruption is implicated in leukemia.
• Plays a role in cancer: CYP26 enzymes are often overexpressed in solid tumors and leukemia, contributing to RA resistance.
• Modulates stem cell fate and regeneration in tissues such as skin, intestine and neural tissue.
• Affects immune function and inflammation through RA-dependent pathways.
• Is a target for therapeutic intervention in dermatological disorders and cancer.
• Provides a mechanism for feedback regulation of RA biosynthesis and signaling.
• Influences neurogenesis and neurodegeneration; altered RA catabolism has been observed in neurodegenerative conditions.
• Serves as a model for studying cytochrome P450 enzyme specificity and regulation.
• Enables precise control of cell differentiation protocols in regenerative medicine.
What Happens During retinoic acid catabolic process?
Uptake and availability of retinoic acid
In simple terms: Before retinoic acid can be broken down, it must be present in the cell, often bound to carrier proteins.
Retinoic acid enters cells or is synthesized locally from retinaldehyde. Cellular retinoic acid-binding proteins (CRABPs) facilitate its solubilization and presentation to catabolic enzymes. The availability of RA for catabolism is influenced by its synthesis by retinaldehyde dehydrogenases (RALDHs) and its binding to CRABP2, which can shuttle RA to the nucleus or to degradation pathways.
Initial oxidation by CYP26 enzymes
In simple terms: Specialized enzymes called CYP26 attach oxygen to retinoic acid, starting its breakdown.
The first committed step in RA catabolism is hydroxylation, primarily at the C4 position, catalyzed by cytochrome P450 enzymes of the CYP26 family (CYP26A1, CYP26B1, CYP26C1). These enzymes convert all-trans-retinoic acid to 4-hydroxy-retinoic acid, which can be further oxidized to 4-oxo-retinoic acid and other polar metabolites. CYP26 expression is induced by RA itself, creating a negative feedback loop that limits RA action.
Further oxidation and metabolite formation
In simple terms: The initial product is further modified into more water-soluble forms that can be excreted.
Following 4-hydroxylation, additional oxidation steps generate 4-oxo-RA and other metabolites such as 18-hydroxy-RA and 5,8-epoxy-RA. These metabolites are generally less active or inactive in transcriptional assays and are more polar, facilitating their clearance from the cell. The exact spectrum of metabolites can vary by tissue and species, reflecting differences in CYP26 expression and activity.
Termination of retinoic acid signaling
In simple terms: Breaking down retinoic acid stops its ability to turn genes on or off.
By reducing intracellular RA concentrations, catabolism terminates the activation of retinoic acid receptors (RARs) and retinoid X receptors (RXRs), which are ligand-dependent transcription factors. This allows cells to reset their transcriptional programs and respond to new signals. The balance between RA synthesis and catabolism thus determines the duration and intensity of RA signaling.
Clearance and excretion
In simple terms: The breakdown products are removed from the cell and eventually from the body.
Polar RA metabolites are exported from cells and can be further metabolized in the liver or excreted in bile and urine. This clearance prevents accumulation of potentially toxic retinoids and maintains systemic retinoid homeostasis.
Key Genes Involved in GO:0034653 retinoic acid catabolic process
The following genes and proteins are central to the retinoic acid catabolic process (GO:0034653), based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CYP26A1 | Primary retinoic acid 4-hydroxylase; catalyzes the first step of RA catabolism | Knockout leads to excess RA and developmental defects; target in cancer and differentiation studies |
| CYP26B1 | RA hydroxylase with tissue-specific expression; important in limb and neural development | Mutations cause developmental disorders; studied in embryogenesis and cancer |
| CYP26C1 | RA hydroxylase; contributes to RA clearance in specific tissues | Less studied; potential role in retinoid homeostasis and disease |
| CRABP2 | Cellular retinoic acid-binding protein 2; binds RA and modulates its availability for catabolism | Implicated in solid tumors; affects RA sensitivity |
| CRABP1 | Cellular retinoic acid-binding protein 1; may sequester RA | Studied in development and cancer |
| RALDH1 (ALDH1A1) | Retinaldehyde dehydrogenase; synthesizes RA, opposing catabolism | Target for modulating RA levels in stem cells and cancer |
| RALDH2 (ALDH1A2) | Major RA-synthesizing enzyme in embryos | Knockout causes severe developmental defects |
| RALDH3 (ALDH1A3) | RA synthesis in specific tissues | Linked to cancer stem cell maintenance |
| RARα (NR1B1) | Retinoic acid receptor; mediates RA signaling and induces CYP26 expression | Target of therapies in APL; feedback regulation of catabolism |
| RARβ (NR1B2) | RA receptor; regulates gene expression and feedback | Tumor suppressor in some cancers |
| RARγ (NR1B3) | RA receptor; involved in skin and stem cell biology | Studied in differentiation and cancer |
| RXRα (NR2B1) | Retinoid X receptor; heterodimerizes with RARs | Central to RA signaling; affects catabolism indirectly |
| RXRβ (NR2B2) | RXR family member; modulates RA responses | Less studied; potential role in metabolism |
| RXRγ (NR2B3) | RXR family member; tissue-specific functions | Studied in brain and muscle |
| CYP2C8 | Cytochrome P450 enzyme with RA hydroxylase activity | May contribute to RA catabolism in liver and other tissues |
| CYP3A4 | Cytochrome P450 enzyme; can oxidize retinoids | Involved in drug metabolism and potential RA clearance |
| TET2 | Epigenetic regulator; activated by RA and ascorbate, influencing differentiation | Mutated in leukemia; linked to RA sensitivity |
| ASXL1 | Chromatin regulator; interacts with RA signaling | Mutated in myeloid malignancies; affects RA response |
How Is retinoic acid catabolic process Regulated?
Retinoic acid catabolism is regulated at multiple levels. The expression of CYP26 enzymes is induced by retinoic acid itself through RAR/RXR heterodimers, forming a negative feedback loop that prevents excessive RA signaling. This feedback is modulated by microRNAs and epigenetic factors. In addition, CYP26 activity can be influenced by post-translational modifications and by the availability of cofactors such as NADPH and cytochrome P450 reductase. Other signaling pathways, including those involving TET2 and ascorbate, can synergize with RA to affect differentiation and indirectly influence catabolism. The balance between RA synthesis (RALDHs) and catabolism (CYP26s) is also controlled by tissue-specific transcription factors and developmental cues.
retinoic acid catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CYP26A1 | Acute myeloid leukemia; RA resistance | Knockout or overexpression in AML cell lines (e.g., HL-60, NB4) |
| CYP26B1 | Solid tumors; developmental defects | CRISPR knockout in cancer cell lines and zebrafish models |
| CRABP2 | Solid tumors; altered RA sensitivity | Knockdown/knockout in breast cancer cell lines |
| RARα | Acute promyelocytic leukemia | Point mutation (e.g., PML-RARα) in hematopoietic cells |
| TET2 | Myeloid leukemia; epigenetic regulation | Knockout in leukemia cell lines; RA/ascorbate treatment |
Acute myeloid leukemia (AML) and other leukemias
In acute promyelocytic leukemia (APL), a subtype of AML, the PML-RARα fusion protein disrupts RA signaling, and pharmacological doses of RA are used to induce differentiation. Altered expression of CYP26 enzymes can contribute to RA resistance, and RA catabolism influences the response to differentiation therapy. TET2 mutations, which affect epigenetic regulation, also modulate RA sensitivity in myeloid malignancies.
Solid tumors
CYP26A1 and CYP26B1 are overexpressed in several solid tumors, including breast, colorectal and neuroblastoma, where they may reduce intracellular RA levels and promote tumor growth or resistance to retinoid therapy. CRABP2 expression is also altered in solid tumors and affects RA bioavailability. Targeting RA catabolism is therefore considered a potential therapeutic strategy.
Developmental disorders
Proper embryonic development requires precise spatial and temporal control of RA levels. Mutations or dysregulation of CYP26 enzymes lead to excess or deficient RA signaling, causing limb defects, neural tube defects and craniofacial abnormalities in animal models. These findings highlight the importance of RA catabolism in human congenital disorders.
Neurodegeneration and neurological disorders
Retinoic acid signaling is important for neurogenesis and neuronal maintenance. Dysregulated RA catabolism has been implicated in neurodegenerative conditions, although the exact mechanisms remain under investigation. Modulating RA levels via CYP26 inhibition is being explored for neuroprotection.
From retinoic acid catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CYP26A1 increase RA signaling and differentiation? | CRISPR knockout of CYP26A1 in cell lines (e.g., HEK293, HL-60) |
| What is the effect of a specific CYP26B1 point mutation on enzyme activity? | CRISPR point mutation knock-in in cancer cell lines |
| Can we tag endogenous CYP26A1 to track its localization? | Knock-in of fluorescent tag (e.g., GFP) at CYP26A1 locus |
| Does overexpression of CRABP2 alter RA catabolism and tumor growth? | Overexpression of CRABP2 in cancer cell lines and xenografts |
| Which genes are essential for RA catabolism in a genome-wide manner? | CRISPR library screening with RA-responsive reporters |
| How does TET2 mutation affect RA-induced differentiation? | Knockout or point mutation of TET2 in leukemia cells |
How to Study the retinoic acid catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS | Concentrations of RA and its metabolites | Quantifying catabolic flux in cells/tissues |
| RARE-luciferase reporter | RA signaling activity | Screening for modulators of RA catabolism |
| RNA-seq | Global gene expression changes | Identifying RA target genes and feedback regulation |
| CRISPR knockout | Loss-of-function of catabolic genes | Studying the role of CYP26 enzymes in differentiation |
| CRISPR point mutation | Specific amino acid changes in enzymes | Dissecting catalytic residues of CYP26 |
| Knock-in tagging | Localization and dynamics of catabolic enzymes | Imaging CYP26 in live cells |
| Overexpression | Gain-of-function of catabolic genes | Testing if increased catabolism reduces RA signaling |
| CRISPR library screening | Genome-wide identification of regulators | Discovering novel genes in RA catabolism |
Quantification of retinoids by LC-MS/MS
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold standard for measuring retinoic acid and its metabolites in cells and tissues. This method allows precise quantification of RA catabolism by detecting 4-hydroxy-RA, 4-oxo-RA and other polar metabolites. It is used to validate the impact of genetic perturbations (e.g., CYP26 knockout) on RA levels.
Reporter assays for retinoic acid signaling
RA-responsive luciferase reporters (e.g., RARE-luciferase) measure the net effect of RA synthesis and catabolism on transcriptional activity. These assays are useful for screening compounds or genetic modifiers that alter RA catabolism. They can be combined with CRISPR screens to identify regulators.
Transcriptomic and proteomic profiling
RNA-seq and proteomics can reveal changes in gene expression and protein abundance upon modulation of RA catabolism. For example, knockout of CYP26 enzymes leads to altered expression of RA target genes, which can be monitored by RNA-seq. Proteomics can identify interacting partners of catabolic enzymes.
Enzyme activity assays
In vitro assays using recombinant CYP26 enzymes or cell lysates measure the conversion of retinoic acid to hydroxylated products. These assays help determine kinetic parameters and the impact of mutations. They are often coupled with HPLC or LC-MS detection.
How CRISPR Can Be Used to Study GO:0034653 retinoic acid catabolic process
Knockout
CRISPR knockout of CYP26A1, CYP26B1 or CYP26C1 in cell lines (e.g., HEK293, HL-60, cancer cells) leads to accumulation of retinoic acid and enhanced RA signaling, which can be measured by reporter assays and LC-MS/MS. These models are valuable for studying the consequences of impaired RA catabolism in differentiation and proliferation.
Point Mutation
CRISPR point mutation can be used to introduce specific amino acid substitutions in CYP26 enzymes to dissect their catalytic mechanism or to model human mutations associated with disease. For example, mutating the heme-binding domain can abolish enzymatic activity, providing a control for knockout studies.
Knock-in
Knock-in of fluorescent tags (e.g., GFP, mCherry) at the endogenous CYP26A1 locus allows real-time imaging of enzyme localization and dynamics in response to RA. Knock-in of reporter cassettes (e.g., luciferase) under the control of the CYP26 promoter can monitor transcriptional feedback.
Overexpression
Overexpression of CYP26 enzymes or CRABP2 in cell lines reduces intracellular RA levels and can blunt RA-induced differentiation. This approach is useful to test whether increased catabolism contributes to RA resistance in cancer cells.
How EDITGENE Supports retinoic acid catabolic process Research
Researchers studying retinoic acid catabolic process-related genes often need to determine whether a candidate gene is causally involved in RA degradation, how specific mutations affect enzyme activity, and whether modulating catabolism can alter disease phenotypes. EDITGENE provides comprehensive CRISPR cell model services to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for retinoic acid catabolic process research.
Frequently Asked Questions About retinoic acid catabolic process
What is retinoic acid catabolic process (GO:0034653)?
It is the set of biochemical reactions that break down retinoic acid, the active form of vitamin A, into less active metabolites, thereby terminating its signaling.
What genes are involved in retinoic acid catabolic process?
Key genes include CYP26A1, CYP26B1, CYP26C1, CRABP1, CRABP2, and cytochrome P450 enzymes such as CYP2C8 and CYP3A4.
Which enzymes catalyze retinoic acid catabolism?
Cytochrome P450 family 26 enzymes (CYP26A1, CYP26B1, CYP26C1) are the primary enzymes that hydroxylate retinoic acid, initiating its breakdown.
Why is retinoic acid catabolism important in development?
It ensures that retinoic acid signals are transient and localized, which is essential for proper embryonic patterning and organ formation.
How is retinoic acid catabolism regulated?
It is regulated by a negative feedback loop where retinoic acid induces CYP26 expression via RAR/RXR, and by microRNAs and epigenetic factors.
What diseases are linked to defects in retinoic acid catabolism?
Dysregulation is associated with acute myeloid leukemia, solid tumors, developmental disorders and possibly neurodegeneration.
How can I study retinoic acid catabolic process in the lab?
Common methods include LC-MS/MS for retinoid quantification, reporter assays, CRISPR knockout/knock-in of CYP26 genes, and transcriptomic profiling.
What is the role of CYP26A1 in retinoic acid catabolism?
CYP26A1 is a major enzyme that hydroxylates retinoic acid at the C4 position, initiating its degradation and limiting RA signaling.
Can CRISPR be used to model retinoic acid catabolism disorders?
Yes, CRISPR knockout, point mutation and knock-in models in cell lines and animal models can recapitulate disease-associated alterations in RA catabolism.
What services does EDITGENE offer for retinoic acid catabolism research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression cell models, library screening and bioinformatics for genes in the retinoic acid catabolic pathway.
Conclusion
The retinoic acid catabolic process (GO:0034653) is a fundamental mechanism that controls the duration and intensity of retinoic acid signaling, with profound implications for development, differentiation and disease. Key enzymes such as CYP26A1, CYP26B1 and CYP26C1, along with binding proteins and receptors, orchestrate this process in a tightly regulated manner. Dysregulation of RA catabolism contributes to leukemia, solid tumors and developmental defects, making it an attractive target for therapeutic intervention. Researchers can leverage CRISPR-based cell models and advanced analytical methods to dissect the molecular players and regulatory networks of RA catabolism. EDITGENE offers a comprehensive suite of services to support such studies, from knockout and knock-in models to library screening and bioinformatics, accelerating discoveries in retinoid biology and disease.
References
- 1. Ott DB et al.. 1979. Retinoic acid--a review.. Am J Clin Nutr 32(12):2522-31 PMID: 389022
- 2. Leesang TE et al.. 2025. Retinoic acid and ascorbate synergize to suppress myeloid leukemia via TET2 activation.. Cell Rep 44(10):116379 PMID: 41037397
- 3. Drumea K et al.. 2008. Retinoic acid signaling in myelopoiesis.. Curr Opin Hematol 15(1):37-41 PMID: 18043244
- 4. Gilardi F et al.. 2014. RXRs: collegial partners.. Subcell Biochem 70:75-102 PMID: 24962882
- 5. Belyaeva OV et al.. 2019. Generation of Retinaldehyde for Retinoic Acid Biosynthesis.. Biomolecules 10(1) PMID: 31861321
- 6. Nervi C et al.. 2014. RARs and microRNAs.. Subcell Biochem 70:151-79 PMID: 24962885
- 7. Jiao X et al.. 2020. Cellular Retinoic-Acid Binding Protein 2 in Solid Tumor.. Curr Protein Pept Sci 21(5):507-516 PMID: 32013828
- 8. Chytil F. 1986. Retinoic acid: biochemistry and metabolism.. J Am Acad Dermatol 15(4 Pt 2):741-7 PMID: 3021827
